Seribantumab

DRUG3 trials

Sponsors

Elevation Oncology, Ottawa Hospital Research Institute

Conditions

Bile Duct CancerBladder CancerBreast CancerCholangiocarcinomaColorectal CancerEsophageal CancerGallbladder CancerHead and Neck Cancer

Phase 2

Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer

TerminatedNCT03241810

Elevation OncologyMetastatic Breast Cancer

Start: 2017-08-15End: 2018-11-30Updated: 2020-09-02

Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

TerminatedNCT04383210

Elevation OncologyBile Duct Cancer, Bladder Cancer, Breast Cancer +14

Start: 2020-09-29End: 2024-02-28Updated: 2025-04-03

Single Patient Protocol for an NRG1 Fusion Positive Metastatic Pancreatic Cancer Patient Using Seribantumab

CompletedNCT04790695

Ottawa Hospital Research InstituteMetastatic Pancreatic Cancer

Start: 2021-03-29End: 2021-12-22Updated: 2022-01-12

Related Papers

CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 ( <i>NRG1</i> ) Fusions

JCO Precision Oncology2025-08-01

Abstract CT229: CRESTONE: A Phase 2 study of seribantumab in adult patients with neuregulin-1 (NRG1) fusion positive locally advanced or metastatic solid tumors

Cancer Research2023-04-1416 citations

Abstract 921: Identification of <i>NRG1</i> fusions in patients with solid tumors: analysis from a real-world community oncology network

Cancer Research2023-04-042 citations

CRESTONE: Initial efficacy and safety of seribantumab in solid tumors harboring <i>NRG1</i> fusions.

Journal of Clinical Oncology2022-06-0138 citations

Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors

Investigational New Drugs2021-07-1128 citations

CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusions—A phase II study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210).

Journal of Clinical Oncology2021-01-205 citations

Abstract PO-003: CRESTONE – Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) Fusions – A phase 2 study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210)

Cancer Research2020-11-137 citations

Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany.

2020-11-115 citations